Comparison of the efficacy and safety of paclitaxel‐eluting coroflex please stents and paclitaxel‐eluting stents in patients with coronary artery disease: A randomized PIPA trial

Kim, Hyun‐Sook; Park, Seung‐Jung; Park, Duk‐Woo; Park, Seong-Wook; Cheong, Sang-Sig; Lee, Sang-Gon; Cho, Byung Ryul; Lee, Seung-Wook; Lee, Nae–Hee; Lee, Keun

doi:10.1002/ccd.23440

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trials that used DES with an eluting drug other than those compared (as listed in the Methods), balloon angioplasty alone, or comparison with coronary artery bypass graft surgery were excluded. In addition, we excluded trials that tested 2 stents that eluted the same drug but differed in stent designs (PERSEUS [Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System], 8 PIPA [Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent], 9 and the PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions 10 ) because these trials did not provide head-to-head comparisons of 2 different DES or DES versus BMS. 11,12 …”

Section: Methods Eligibility Criteriamentioning

confidence: 99%

Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents

et al. 2012

View full text Add to dashboard Cite

Background-Drug-eluting stents (DES) have been in clinical use for nearly a decade; however, the relative short-and long-term efficacy and safety of DES compared with bare-metal stents (BMS) and among the DES types are less well defined. with each other or against BMS for de novo coronary lesions, enrolling at least 100 patients and with follow-up of at least 6 months. Short-term (Յ1 year) and long-term efficacy (target-vessel revascularization, target-lesion revascularization) and safety (death, myocardial infarction, stent thrombosis) outcomes were evaluated and trial-level data pooled by both mixed-treatment comparison and direct comparison analyses. From 76 randomized clinical trials with 117 762 patient-years of follow-up, compared with BMS, each DES reduced long-term target-vessel revascularization (39%-61%), but the magnitude varied by DES type (EESϳSESϳZES-RϾPESϳZESϾBMS), with a Ͼ42% probability that EES had the lowest target-vessel revascularization rate. There was no increase in the risk of any long-term safety outcomes, including stent thrombosis, with any DES (versus BMS). In addition, there was reduction in myocardial infarction (all DES except PES versus BMS) and stent thrombosis (with EES versus BMS: Rate ratio, 0.51; 95% credibility interval, 0.35-0.73). The safest DES appeared to be EES (Ͼ86% probability), with reduction in myocardial infarction and stent thrombosis compared with BMS. Short-term outcomes were similar to long-term outcomes, with SES, ZES-R, and everolimus-eluting stent being the most efficacious and EES being the safest stent. Conclusions-DES are highly efficacious at reducing the risk of target-vessel revascularization without an increase in any safety outcomes, including stent thrombosis. However, among the DES types, there were considerable differences, such that EES, SES, and ZES-R were the most efficacious and EES was the safest stent. (Circulation. 2012;125:2873-2891.)

show abstract

Section: Methods Eligibility Criteriamentioning

confidence: 99%

Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents

et al. 2012

View full text Add to dashboard Cite

show abstract

“…These techniques primarily exploit the degradation of polymers by the lysosomal enzymes such as cysteine proteases, particularly CtB and CtL1619202122. In particular, PLG has been used as a macromolecular carrier for drug delivery16 and PLG in combination with paclitaxel (PG-TXL) has advanced to clinical trials2324. Since the development and application of targeted delivery of anticancer agents using PLG as the drug carrier is emerging2324, we envisage that, in the long term, the proposed CEST imaging technology has the potential to monitor PLG conjugated drug delivery and therapeutic response of tumors.…”

Section: Resultsmentioning

confidence: 99%

In vivo Magnetic Resonance Imaging of Tumor Protease Activity

Haris

Singh

Mohammed

et al. 2014

Sci Rep

View full text Add to dashboard Cite

Increased expression of cathepsins has diagnostic as well as prognostic value in several types of cancer. Here, we demonstrate a novel magnetic resonance imaging (MRI) method, which uses poly-L-glutamate (PLG) as an MRI probe to map cathepsin expression in vivo, in a rat brain tumor model. This noninvasive, high-resolution and non-radioactive method exploits the differences in the CEST signals of PLG in the native form and cathepsin mediated cleaved form. The method was validated in phantoms with known physiological concentrations, in tumor cells and in an animal model of brain tumor along with immunohistochemical analysis. Potential applications in tumor diagnosis and evaluation of therapeutic response are outlined.

show abstract

Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis

Navarese

Tandjung

Claessen

et al. 2013

BMJ

208

125

View full text Add to dashboard Cite

Objectives To investigate the safety and efficacy of durable polymer drug eluting stents (DES) and biodegradable polymer biolimus eluting stents (biolimus-ES).Design Network meta-analysis of randomised controlled trials.Data sources and study selection Medline, Google Scholar, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) database search for randomised controlled trials comparing at least two of durable polymer sirolimus eluting stents (sirolimus-ES) and paclitaxel eluting stents (paclitaxel-ES), newer durable polymer everolimus eluting stents (everolimus-ES), Endeavor and Resolute zotarolimus eluting stents (zotarolimus-ES), and biodegradable polymer biolimus-ES.Primary outcomes Safety (death, myocardial infarction, definite or probable stent thrombosis) and efficacy (target lesion and target vessel revascularisation) assessed at up to one year and beyond.Results 60 randomised controlled trials were compared involving 63 242 patients with stable coronary artery disease or acute coronary syndrome treated with a DES. At one year, there were no differences in mortality among devices. Resolute and Endeavor zotarolimus-ES, everolimus-ES, and sirolimus-ES, but not biodegradable polymer biolimus-ES, were associated with significantly reduced odds of myocardial infarction (by 29-34%) compared with paclitaxel-ES. Compared with everolimus-ES, biodegradable polymer biolimus-ES were associated with significantly increased odds of myocardial infarction (by 29%), while Endeavor zotarolimus-ES and paclitaxel-ES were associated with significantly increased odds of stent thrombosis. All investigated DES were similar with regards to efficacy endpoints, except for Endeavor zotarolimus-ES and paclitaxel-ES, which were associated with significantly increased the odds of target lesion and target vessel revascularisations compared with other devices. Direction of results beyond one year did not diverge from the findings for up to one year follow-up. Bayesian probability curves showed a gradient in the magnitude of effect, with everolimus-ES and Resolute zotarolimus-ES offering the highest safety profiles.Conclusions The newer durable polymer everolimus-ES and Resolute zotarolimus-ES and the biodegradable polymer biolimus-ES maintain the efficacy of sirolimus-ES; however, for safety endpoints, differences become apparent, with everolimus-ES and Resolute zotarolimus-ES emerging as the safest stents to date.

show abstract

Comparison of the efficacy and safety of paclitaxel‐eluting coroflex please stents and paclitaxel‐eluting stents in patients with coronary artery disease: A randomized PIPA trial

Abstract: The Coroflex™ Please stent resulted in similar angiographic and clinical outcomes as the Taxus™ Liberte stent in patients with coronary artery lesions.

Cited by 3 publications

References 17 publications

Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents

Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents

In vivo Magnetic Resonance Imaging of Tumor Protease Activity

Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis

Contact Info

Product

Resources

About